Clinical Trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-03
notable Trial sites expanded: 1 -> 7 locations 2026-06-19
Trial Details
NCT Number NCT07473726
Lead Sponsor Shanghai Henlius Biotech
Conditions Advanced/Metastatic Solid Tumors
Enrollment 72 participants
Start Date 2026-06-30
Primary Completion 2027-03 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-02